Background: Nephron sparing surgery for renal tumors has evolved as the standard of care for resectable renal tumors. Laparoscopic partial nephrectomy (PN) has gained recognition after technical refinements were able to match the well-established criteria for open partial nephrectomy. Laparoendoscopic surgery (LESS) is one of the approaches to further minimize invasiveness of laparoscopic surgery.
Objective: We report our initial experience with LESS partial nephrectomy in single-incision transumbilical surgery technique (SITUS) in daily clinical practice.
Design, Setting, And Participants: From 2010, patients undergoing SITUS-PN were prospectively evaluated. Patients with small, solitary or multiple, exophytic-enhancing renal masses were selected, whereas patients with solitary kidney, endophytic or hilar tumors were excluded. Important clinical data, PADUA and RENAL score, were assessed prospectively.
Measurements: Patients' characteristics, perioperative, hematologic and pathologic data as well as pain evaluation using the visual analogue pain scale (VAPS) were assessed.
Results And Limitations: A total of 13 patients underwent LESS-PN/SITUS-PN (6 right and 7 left renal units). One patient was converted to conventional laparoscopy requiring two additional ports to treat bleeding from renal vessels. Pathology revealed renal cell carcinoma in nine patients, oncocytoma in one and benign cyst in three patients. No positive surgical margin was observed. The mean blood loss was 2.1 g/dl [range 0.5-4.5 g/dl] in hemoglobin. Minimal discomfort was noted at discharge (VAPS = 0.2 ± 0.6 [range 0-2]/10].
Conclusion: LESS partial nephrectomy in SITUS technique is feasible for selected exophytic tumors and has been integrated into our armamentarium for nephron sparing minimally invasive surgical treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00345-014-1320-7 | DOI Listing |
Introduction: Nivolumab can cause various immune-related adverse events; it rarely induces Vogt-Koyanagi-Harada-disease-like uveitis. Vogt-Koyanagi-Harada-disease is reported to be closely associated with human leukocyte antigen-DR4.
Case Presentation: A 68-year-old man with metastatic renal cancer underwent nephrectomy.
Introduction: Renal artery pseudoaneurysm is a rare yet serious complication following percutaneous nephrolithotomy, especially in patients with solitary kidneys. Effective management is crucial to prevent further renal damage.
Case Presentation: We report a case of a 41-year-old male with a solitary kidney who experienced gross hematuria and renal insufficiency 3 months after percutaneous nephrolithotomy.
Sci Rep
January 2025
Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
To investigate the potential association between body mass index (BMI) and the clinicopathological features of patients with clear cell renal cell carcinoma (ccRCC). We retrospectively analyzed data from 2541 patients who underwent partial or radical nephrectomy for renal masses between 2013 and 2023 in a single institution. Patients were divided into normal-weight, overweight, and obese groups based on the Chinese BMI classification.
View Article and Find Full Text PDFWorld J Urol
January 2025
Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
Purpose: Immune Checkpoints Inhibitors (ICI) have changed the therapeutic landscape of metastatic renal cell carcinoma first-line treatment with complete response (CR) at metastatic sites observed in 10 to 15% of cases. Delayed nephrectomy could be discussed for patients having a clinical benefit from immunotherapy-based treatment. However, it is unclear whether prior immunotherapy exposure adversely influences the complexity of surgery.
View Article and Find Full Text PDFBJUI Compass
December 2024
Desai Sethi Urology Institute, Miller School of Medicine University of Miami Miami Florida USA.
Objectives: The objectives of this study are to compare the accuracy of warm ischemia times (WITs) derived by a surgical artificial intelligence (AI) software to those documented in surgeon operative reports during partial nephrectomy procedures and to assess the potential of this technology in evaluating postoperative renal function.
Patients And Methods: A surgical AI software (Theator Inc., Palo Alto, CA) was used to capture and analyse videos of partial nephrectomies performed between October 2023 and April 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!